Crohn’s Disease (CD) Treatment Market Growth Outlook Through 2024-2033

Spread the love

Overview and Scope

Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn’s disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

Sizing and Forecast

The crohn’s disease (cd) treatment market size has grown strongly in recent years. It will grow from $11.13 billion in 2023 to $11.76 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of crohn’s disease, growing awareness of the disease, government initiatives, changing lifestyle.

The crohn’s disease (cd) treatment market size is expected to see steady growth in the next few years. It will grow to $14.22 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn’s disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/crohn’s-disease-cd-treatment-global-market-report

Segmentation & Regional Insights

The crohn’s disease (cd) treatment market covered in this report is segmented –

1) By Drug Type: Antibiotics; Amino Salicylates; Corticosteroids; Immunomodulators; Other Drug Types

2) By Route of Administration: Oral; Injectable

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores

North America was the largest region in the Crohn’s disease (CD) treatment market in 2023. The regions covered in Crohn’s disease (CD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of inflammatory bowel diseases is expected to propel the growth of the Crohn’s disease (CD) treatment market going forward. Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders primarily affecting the gastrointestinal (GI) tract. Crohn’s disease (CD) treatment offers relief from symptoms, reduces inflammation, promotes remission and enhances the overall quality of life for individuals suffering from chronic inflammatory bowel disease. For instance, in May 2021, according to BioMed Central Ltd., a UK-based scientific open-access publisher, it is expected that between 2020 and 2035, there will be 69 thousand Inflammatory bowel disease cases in Iran, 220 thousand cases in the Middle East, 2.2 million cases in India and 4.5 million cases in East Asia. Therefore, the increasing prevalence of inflammatory bowel diseases drives the Crohn’s disease (CD) treatment market.

Key Industry Players

Major players in the crohn’s disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

The crohn’s disease (cd) treatment market report table of contents includes: